Article Details

Biogen To Receive Potential Royalties For Anti-CD20 Bispecific From Genentech

Retrieved on: 2022-12-21 03:50:59

Tags for this article:

Click the tags to see associated articles and topics

Biogen To Receive Potential Royalties For Anti-CD20 Bispecific From Genentech. View article details on hiswai:

Excerpt

Biogen and Roche's Genentech have reached an agreement whereby Biogen will receive tiered royalties “in the mid-single digits” on potential sales ...

Article found on: www.geneonline.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up